MedTrace Logo

Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women

NCT02038023 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2018-06-28

Study results available
· View outcomes & findings →

Summary

To determine the percentage of women who achieve anemia correction after a single dose of 1000mg of low molecular weight iron dextran(infed).

Conditions

  • Pregnancy

Interventions

DRUG

Intravaneous iron(low molecular weight iron dextran)

1000 mg of Iron dextran administered over one hour

Sponsors & Collaborators

  • Pharmacosmos A/S

    collaborator INDUSTRY

  • Auerbach Hematology Oncology Associates P C

    lead OTHER

Principal Investigators

  • Michael Auerbach, MD · Auerbach Hematology Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-07-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038023 on ClinicalTrials.gov